fea
liked
1. I gave you stock education for you to get enpowered in your stock trading
2. I post watchlist as guidance on possible stock plays
3. Do not blame me if you baghold because you do FOMO or you don’t scale out.
4. UNFOLLOW me anytime because I do not need people who will blame others for their losses.
5. I will BLOCK anyone who is toxic.
2. I post watchlist as guidance on possible stock plays
3. Do not blame me if you baghold because you do FOMO or you don’t scale out.
4. UNFOLLOW me anytime because I do not need people who will blame others for their losses.
5. I will BLOCK anyone who is toxic.
15
4
fea
reacted to
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, some stocks may get pumped WITHOUT any catal...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, some stocks may get pumped WITHOUT any catal...
94
24
20
fea
liked
Its Friday with shorter trading time. Sleepy already. Some will run and some will get delayed market reaction.
$Applied Therapeutics (APLT.US)$ Crashed after FDA CRL but will resubmit. Dropped from 10 to 1.3 rebounded to 1.95. SI 16%
$PainReform (PRFX.US)$ Microfloat. Up after hours. SI 20%. 0 shares LTB. CTB 436%. If there is no catalyst, microfloats will be a quick play.✔️
$Blue Ocean Acquisition Corp(Delisted) (BOCN.US)$ Merger ...
$Applied Therapeutics (APLT.US)$ Crashed after FDA CRL but will resubmit. Dropped from 10 to 1.3 rebounded to 1.95. SI 16%
$PainReform (PRFX.US)$ Microfloat. Up after hours. SI 20%. 0 shares LTB. CTB 436%. If there is no catalyst, microfloats will be a quick play.✔️
$Blue Ocean Acquisition Corp(Delisted) (BOCN.US)$ Merger ...
50
13
7
fea
liked
$Aptevo Therapeutics (APVO.US)$
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
Aptevo Therapeutics (NASDAQ:APVO) announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session and present at Cambridge Healthcare Institute's Pep Talk conference in January 2025.
The presentation will showcase how Aptevo uses its ADAPTIR and ADAPTIR-FLEX platforms to accelerate cancer therapy developme...
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
Aptevo Therapeutics (NASDAQ:APVO) announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session and present at Cambridge Healthcare Institute's Pep Talk conference in January 2025.
The presentation will showcase how Aptevo uses its ADAPTIR and ADAPTIR-FLEX platforms to accelerate cancer therapy developme...
2
1
fea
liked
$Aptevo Therapeutics (APVO.US)$
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
Aptevo Therapeutics (NASDAQ: APVO) reports promising early results from its RAINIER trial, where the first patient treated with mipletamig achieved a 90% reduction in leukemic blasts within 30 days.
The trial evaluates mipletamig as a frontline therapy for Ac...
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
Aptevo Therapeutics (NASDAQ: APVO) reports promising early results from its RAINIER trial, where the first patient treated with mipletamig achieved a 90% reduction in leukemic blasts within 30 days.
The trial evaluates mipletamig as a frontline therapy for Ac...
1